1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023

The report on breast cancer therapeutics: pipeline analysis market studies the future market of breast cancer drugs on the basis of the molecules which are currently under pipeline. Breast cancer usually originates from the inner lining of milk ducts or lobules responsible for supplying the milk. This is a malignant type of tumor that can spread to other cells present in the body. The type of cancer which starts in lobules is referred as lobular carcinoma, while the other that develops from milk ducts is called ductal carcinoma. Breast cancer is the most common type of invasive cancer affecting women worldwide. The drugs that are under clinical trial phase III have been considered to estimate the market for the forecast period from 2015 to 2023. Stakeholders for this report include the companies engaged in research and development of breast cancer drugs, and sponsoring of clinical trials studies and new entrants that are planning to invest in the breast cancer pipeline drugs.

The executive summary section of the breast cancer therapeutics: pipeline analysis market report summarizes the market analysis of the major pipeline drugs in the breast cancer market. It also provides information about the key pipeline molecules available in phase I and phase II clinical trials along with a list of major market players who are sponsoring these studies.

The market overview section of the report provides a detailed qualitative information about breast cancer. Factors such as epidemiology of breast cancer across different geographical regions, types of breast cancer, and other possible treatments for breast cancer are explained along with relevant statistics in this section. A list of companion diagnostic devices with respect to the major target drugs used for the treatment of breast cancer is also included in the report to provide a brief idea about the current scenario of the breast cancer market. Major business strategies applied in the market by the major players to strengthen their breast cancer pipeline have also been explained with the help of relevant examples. All these factors have been provided to help new entrants and market players understand the important aspects of the breast cancer market in the current scenario and decide upon strategic decisions that would assist them in generating a strong pipeline for breast cancer therapeutic drugs.

Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine + Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023.

A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi.

Table Of Contents

Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Secondary Research
1.3.2 Primary Research
1.4 Assumptions

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.1.1 Epidemiology
3.1.2 Types of Breast Cancer
3.1.2.1 HER2+
3.1.2.2 Triple-negative breast cancer
3.1.2.3 Hormone Receptor Positive Breast Cancer
3.1.3 Companion Diagnostics
3.1.4 Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
3.1.5 Other Treatments for Breast Cancer
3.1.5.1 Surgery
3.1.5.2 Radiation Therapy
3.1.5.3 Bone-directed Therapy
3.1.5.4 Radiofrequency Ablation
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Strong pipeline with a perfect blend of small molecules, biologics, immunotherapies and other therapies
3.2.2 Restraints
3.2.2.1 The overall high survival period delivered by currently FDA approved treatments are not cost-efficient especially in the developing regions
3.2.3 Opportunities
3.2.3.1 Development of immunotherapy and biological therapy treatments along with novel drug delivery systems add advantage over the current conventional treatments
3.3 Business Strategies Applied in the Market
3.3.1 Novel Treatments for Breast Cancer
3.3.1.1 Magnetic Chemotherapy
3.3.1.2 Gene Therapy
3.3.1.3 Novel Drugs for Breast Cancer
3.3.2 Mergers and Acquisitions in the Breast Cancer Market

Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III)
4.1 Overview
4.1.1 Global Breast Cancer Therapeutics Market Revenue, by Drugs (Phase III), 2015 - 2023 (USD Million)
4.2 Phase III Drug Candidates
4.2.1 Overview
4.2.2 Palbociclib (PD-0332991) + Fulvestrant
4.2.2.1 Global Palbociclib (PD-0332991) + Fulvestrant Market Revenue, 2016 - 2023 (USD Million)
4.2.3 NK105
4.2.3.1 Global NK 105 Market Revenue, 2017 - 2023 (USD Million)
4.2.4 BKM 120
4.2.4.1 Global BKM 120 Market Revenue, 2017 - 2023 (USD Million)
4.2.5 NKTR-102
4.2.5.1 Global NKTR-102 Market Revenue, 2016 - 2023 (USD Million)
4.2.6 Neratinib (PB272)
4.2.6.1 Global Neratinib Market Revenue, 2015 - 2023 (USD Million)
4.2.7 Olaparib
4.2.7.1 Global Olaparib Market Revenue, 2015 - 2023 (USD Million)
4.2.8 DOXIL
4.2.8.1 Global DOXIL Market Revenue, 2016 - 2023 (USD Million)
4.2.9 ABP 980
4.2.9.1 Global ABP 980 Market Revenue, 2017 - 2023 (USD Million)
4.2.10 CT-P6
4.2.10.1 Global CT P-6 Market Revenue, 2017 - 2023 (USD Million)
4.2.11 Trastuzumab emtansine (Kadcyla) + Pertuzumab (Perjeta)
4.2.11.1 Global Trastuzumab Emtansine Market Revenue, 2017 - 2023 (USD Million)
4.3 Phase II Drug Candidates
4.4 Phase I Drug candidates

Chapter 5 Recommendations
5.1 Increasing market share through acquisitions and mergers
5.2 Undertaking rigorous RandD initiatives
5.3 Developing biological drugs

Chapter 6 Company Profiles
6.1 AstraZeneca plc
6.1.1 Company Overview
6.1.2 Financial Overview
6.1.3 Product Pipeline
6.1.4 Business Strategies
6.1.4.1 Partnerships
6.1.4.2 Acquisitions and Collaborations
6.1.5 Recent Developments
6.2 Eisai Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Overview
6.2.3 Product Portfolio
6.2.4 Business Strategies
6.2.5 Recent Developments
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Overview
6.3.3 Product Portfolio
6.3.4 Business Strategies
6.3.5 Recent Developments
6.4 F. Hoffmann-La Roche Ltd.
6.4.1 Company Overview
6.4.2 Financial Overview
6.4.3 Product Portfolio
6.4.4 Business Strategies
6.4.5 Recent Developments
6.5 GlaxoSmithKline plc
6.5.1 Company Overview
6.5.2 Financial Overview
6.5.3 Product Portfolio
6.5.4 Business Strategies
6.5.5 Recent Developments
6.6 Novartis International AG
6.6.1 Company Overview
6.6.2 Financial Overview
6.6.3 Product Portfolio
6.6.4 Business Strategies
6.6.5 Recent Developments
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Overview
6.7.3 Product Portfolio
6.7.4 Business Strategies
6.7.5 Recent Developments
6.8 Sanofi
6.8.1 Company Overview
6.8.2 Financial Overview
6.8.3 Product Portfolio
6.8.4 Business Strategies
6.8.5 Recent Developments
List of Figures

FIG. 1 Breast Cancer Therapeutics: Pipeline Analysis Market Segmentation
FIG. 2 Global Palbociclib (PD-0332991) + Fulvestrant Market Revenue, 2016 - 2023 (USD Million)
FIG. 3 Global NK 105 Market Revenue, 2017 - 2023 (USD Million)
FIG. 4 Global BKM 120 Market Revenue, 2017 - 2023 (USD Million)
FIG. 5 Global NKTR-102 Market Revenue, 2016 - 2023 (USD Million)
FIG. 6 Global Neratinib Market Revenue, 2015 - 2023 (USD Million)
FIG. 7 Global Olaparib Market Revenue, 2015 - 2023 (USD Million)
FIG. 8 Global DOXIL Market Revenue, 2016 - 2023 (USD Million)
FIG. 9 Global ABP 980 Market Revenue, 2017 - 2023 (USD Million)
FIG. 10 Global CT P-6 Market Revenue, 2017 - 2023 (USD Million)
FIG. 11 Global Trastuzumab Emtansine Market Revenue, 2017 - 2023 (USD Million)
FIG. 12 Astra Zeneca plc: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 13 Eisai Co., Ltd.: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 14 Eli Lilly and Company: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 15 F. Hoffmann-La Roche Ltd: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 16 GlaxoSmithKline plc: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 17 Novartis International AG: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 18 Pfizer, Inc.: Annual Revenue, 2012 - 2014 (USD Million)
FIG. 19 Sanofi: Annual Revenue, 2012 - 2014 (USD Million)
List of Tables

TABLE 1 Major Molecules in Clinical Trial Phase II Breast Cancer Pipeline
TABLE 2 Major Molecules in Clinical Trial Phase I Breast Cancer Pipeline
TABLE 3 Five-year Survival Rate in Various Stages of Breast Cancer
TABLE 4 Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 5 Global Breast Cancer Therapeutics Market Revenue, by Drugs (Phase III), 2013 - 2023 (USD Million)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Breast Cancer: Analytical Tool

Breast Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Global Breast Cancer Screening Tests Market - Industry Analysis and Market Forecast(2016 - 2021)

Global Breast Cancer Screening Tests Market - Industry Analysis and Market Forecast(2016 - 2021)

  • $ 4250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

Breast cancer screening is carried out to detect cancer in its early stages, and ensure timely treatment of the patients. The American Cancer Society states that breast cancer is the most common cance ...

Global Breast Cancer Drug Market Research Report 2016

Global Breast Cancer Drug Market Research Report 2016

  • $ 2850
  • Industry report
  • October 2016
  • by 9Dimen Research

2016 Global Breast Cancer Drug Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Breast Cancer Drug industry, focusing on the main regions ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.